we got it:
gw
MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 17, 1998--VIVUS
Inc. (NASDAQ:VVUS) today announced approval by the Medicines Control
Agency of the United Kingdom (MCA) to begin commercial production and
shipment of MUSE(R) (alprostadil) from its new 90,000 square foot
Lakewood, New Jersey facility.
"This regulatory milestone will allow VIVUS to ship MUSE
manufactured in our new US facility to Astra AB for distribution in
the United Kingdom, and upon registration, to additional European
countries," said Carol Karp, Vice President of Regulatory Affairs.
"The existing plant will continue to supply MUSE to the United States,
and other countries which rely on the US Food and Drug Administration
(FDA) for clearance."
Founded in 1991, VIVUS, Inc. is a leader in the development of
advanced therapeutic systems for the treatment of erectile
dysfunction, commonly referred to as impotence. VIVUS has pioneered a
novel therapy for erectile dysfunction known as the transurethral
system for erection. This therapy consists of a proprietary,
non-invasive drug delivery system that delivers pharmacologic agents
via the urethra.
CONTACT: VIVUS
Nina W. Ferrari or David Yntema, 650/934-5200
KEYW |
